The association between alkylating agent exposure and acute nonlymphocytic leukemia in humans indicates that myeloid cells may be particularly susceptible to mutagenic damage. Alkylating agent mutagenesis is frequently mediated through formation and persistence of a particular DNA base adduct, O6alkylguanine, which preferentially mispairs with thymine rather than cytosine, leading to point mutations. O6alkylguanine is repaired by O6alkylguanine-DNA alkyltransferase (alkyltransferase), a protein that removes the adduct, leaving an intact guanine base in DNA. We measured alkyltransferase activity in myeloid precursors and compared it with levels in other cells and tissues. In peripheral blood granulocytes, monocytes, T lymphocytes, and B lymphocytes, there was an eightfold range of activity between individuals but only a twofold range in the mean activity between cell types. Normal donors maintained stable levels of alkyltransferase activity over time. In bone marrow T lymphocytes and myeloid precursors, there was an eightfold range of alkyltransferase activity between donors. Alkyltransferase activity in the two cell types was closely correlated in individual donors, r = 0.69, P less than 0.005, but was significantly higher in the T lymphocytes than the myeloid precursors, P less than 0.05. Liver contained the highest levels of alkyltransferase of all tissues tested. By comparison, small intestine contained 34%, colon 14%, T lymphocytes 11%, brain 11%, and myeloid precursors 6.6% of the activity found in liver. Thus, human myeloid precursors have low levels of O6alkylguanine-DNA alkyltransferase compared with other tissues. Low levels of this DNA repair protein may increase the susceptibility of myeloid precursors to malignant transformation after exposure to certain alkylating agents.
S L Gerson, K Miller, N A Berger
Title and authors | Publication | Year |
---|---|---|
Myelotoxicity of Temozolomide Treatment in Patients with Glioblastoma Is It Time for a More Mechanistic Approach?
Said MM, Broen MPG, Swart EL, Bartelink IH, Kouwenhoven MCM |
Cancers | 2023 |
The DNA Alkyltransferase Family of DNA Repair Proteins: Common Mechanisms, Diverse Functions.
Tessmer I, Margison GP |
International journal of molecular sciences | 2023 |
Thomas’ Hematopoietic Cell Transplantation: Stem Cell Transplantation
R Nakamura |
Thomas’ Hematopoietic Cell Transplantation: Stem Cell Transplantation | 2016 |
Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy
Murtaza S Nagree, Lucía López-Vásquez, Jeffrey A Medin |
World journal of stem cells | 2015 |
Target-mediated consecutive endonuclease reactions for specific and sensitive homogeneous fluorescence assay of O6-methylguanine-DNA methyltransferase
DV Le, DM Zhou, LJ Tang, JH Jiang, RQ Yu, YZ Wang |
Analytica Chimica Acta | 2013 |
Gene Therapy
S Nimesh |
Gene Therapy | 2013 |
Expression of O<sup>6</sup>-Methylguanine-DNA Methyltransferase Examined by Alkyl-Transfer Assays, Methylation-Specific PCR and Western Blots in Tumors and Matched Normal Tissue
K Ishiguro, K Shyam, PG Penketh, RP Baumann, AC Sartorelli, TJ Rutherford, ES Ratner |
Journal of Cancer Therapy | 2013 |
Extended Survival of Glioblastoma Patients After Chemoprotective HSC Gene Therapy
JE Adair, BC Beard, GD Trobridge, T Neff, JK Rockhill, DL Silbergeld, MM Mrugala, HP Kiem |
Science Translational Medicine | 2012 |
Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma
MW Pitz, M Lipson, B Hosseini, P Lambert, K Guilbert, D Lister, G Schroeder, K Jones, C Mihalicioiu, DD Eisenstat |
Current Oncology | 2012 |
O6-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry
M Christmann, B Verbeek, WP Roos, B Kaina |
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer | 2011 |
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
JC Hassel, A Sucker, L Edler, H Kurzen, I Moll, C Stresemann, K Spieth, C Mauch, K Rass, R Dummer, D Schadendorf |
British Journal of Cancer | 2010 |
Analysis of Self-Inactivating Lentiviral Vector Integration Sites and Flanking Gene Expression in Human Peripheral Blood Progenitor Cells After Alkylator Chemotherapy
N Grund, P Maier, FA Giordano, JU Appelt, M Zucknick, L Li, F Wenz, WJ Zeller, S Fruehauf, H Allgayer, S Laufs |
Human Gene Therapy | 2010 |
Can mutagenicity information be useful in an Integrated Testing Strategy (ITS) for skin sensitization?
G Patlewicz, O Mekenyan, G Dimitrova, C Kuseva, M Todorov, S Kotov, S Stoeva, EM Donner |
SAR and QSAR in Environmental Research | 2010 |
Phase I Study of Temozolomide and Laromustine (VNP40101M) in Patients With Relapsed or Refractory Leukemia
D Rizzieri, S LoRusso, W Tse, K Khan, A Advani, J Moore, V Karsten, A Cahill, SL Gerson |
Clinical Lymphoma, Myeloma & Leukemia | 2010 |
Thin layer chromatography-based assay of O6-methylguanine-DNA methyltransferase activity in tissue
C Robinson, J Palomo, MA Vogelbaum |
Analytical Biochemistry | 2010 |
O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib
AJ Watson, MR Middleton, G McGown, M Thorncroft, M Ranson, P Hersey, G McArthur, ID Davis, D Thomson, J Beith, A Haydon, R Kefford, P Lorigan, P Mortimer, A Sabharwal, O Hayward, GP Margison |
British Journal of Cancer | 2009 |
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6 -methylguanine-DNA methyltransferase activity
TM Horton, G Jenkins, D Pati, L Zhang, ME Dolan, A Ribes-Zamora, AA Bertuch, SM Blaney, SL Delaney, M Hegde, SL Berg |
Molecular cancer therapeutics | 2009 |
DNA repair and cancer stem-like cells – Potential partners in glioma drug resistance?
TC Johannessen, R Bjerkvig, BB Tysnes |
Cancer Treatment Reviews | 2008 |
Reciprocal Relationship between O6-Methylguanine-DNA Methyltransferase P140K Expression Level and Chemoprotection of Hematopoietic Stem Cells
MD Milsom, M Jerabek-Willemsen, CE Harris, A Schambach, E Broun, J Bailey, M Jansen, D Schleimer, K Nattamai, J Wilhelm, A Watson, H Geiger, GP Margison, T Moritz, C Baum, J Thomale, DA Williams |
Cancer research | 2008 |
In vitro erythropoiesis from bone marrow-derived progenitors provides a physiological assay for toxic and mutagenic compounds
J Shuga, J Zhang, LD Samson, HF Lodish, LG Griffith |
Proceedings of the National Academy of Sciences | 2007 |
Bendamustine and cloretazine: Alkylators with sharply contrasting activity in AML
FJ MD |
Leukemia & Lymphoma | 2007 |
Methylation damage response in hematopoietic progenitor cells
I Casorelli, E Pelosi, M Biffoni, AM Cerio, C Peschle, U Testa, M Bignami |
DNA repair | 2007 |
Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals
RJ Hansen, SM Ludeman, SJ Paikoff, AE Pegg, ME Dolan |
DNA repair | 2007 |
Gene Therapy for Cancer
KK Hunt, SA Vorburger, SG Swisher |
2007 | |
Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia
F Giles, D Rizzieri, J Karp, N Vey, F Ravandi, S Faderl, KD Khan, G Verhoef, P Wijermans, A Advani, G Roboz, H Kantarjian, SF Bilgrami, A Ferrant, SM Daenen, V Karsten, A Cahill, M Albitar, G Mufti, S O'Brien |
Journal of Clinical Oncology | 2006 |
A phase I trial of protracted oral fixed-dose temozolomide
SF Jones, FA Greco, VG Gian, FT Miranda, EL Raefsky, JD Hainsworth, NT Willcutt, AF Beschorner, G Kennerly, HA Burris |
Cancer | 2005 |
Phase I Trial of Temozolomide Plus O6 -Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma
JA Quinn, A Desjardins, J Weingart, H Brem, ME Dolan, SM Delaney, J Vredenburgh, J Rich, AH Friedman, DA Reardon, JH Sampson, AE Pegg, RC Moschel, R Birch, RE McLendon, JM Provenzale, S Gururangan, JE Dancey, J Maxwell, S Tourt-Uhlig, JE Herndon, DD Bigner, HS Friedman |
Journal of Clinical Oncology | 2005 |
Role of O6 -Alkylguanine-DNA Alkyltransferase in Protecting against 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-Induced Long-Term Toxicities
RJ Hansen, R Nagasubramanian, SM Delaney, MM Cherian, S Lin, SC Kogan, ME Dolan |
The Journal of pharmacology and experimental therapeutics | 2005 |
A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms
LA Hammond, JR Eckardt, JG Kuhn, SL Gerson, T Johnson, L Smith, RL Drengler, E Campbell, GR Weiss, DD Hoff, EK Rowinsky |
Clinical cancer research | 2004 |
Thymic lymphomas in Wistar rats exposed to N-methyl-N-nitrosourea (MNU)
CA da Franchi, MM Bacchi, CR Padovani, JL Camargo |
Cancer Science | 2003 |
Mismatch repair and response to DNA-damaging antitumour therapies
M Bignami, I Casorelli, P Karran |
European Journal of Cancer | 2003 |
Human–yeast chimeric repair protein protects mammalian cells against alkylating agents: enhancement of MGMT protection
TJ Roth, Y Xu, M Luo, MR Kelley |
Cancer Gene Therapy | 2003 |
Thymic lymphomas in Wistar rats exposed to N‐methyl‐N‐nitrosourea (MNU)
Franchi CA, Bacchi MM, Padovani CR, de Camargo JL |
Cancer Science | 2003 |
Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance
J Ma, M Murphy, PJ O’Dwyer, E Berman, K Reed, JM Gallo |
Biochemical Pharmacology | 2002 |
Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT P140K into hematopoietic stem cells
M Jansen, UR Sorg, S Ragg, M Flasshove, S Seeber, DA Williams, T Moritz |
Cancer Gene Therapy | 2002 |
Down-regulation of DNA repair in human CD34+progenitor cells corresponds to increased drug sensitivity and apoptotic response
C Buschfort-Papewalis, T Moritz, B Liedert, J Thomale |
Blood | 2002 |
Protection of hematopoietic cells fromO6-alkylation damage byO6-methylguanine DNA methyltransferase gene transfer: studies with differentO6-alkylating agents and retroviral backbones
M Jansen, W Bardenheuer, UR Sorg, S Seeber, M Flasshove, T Moritz |
European Journal of Haematology | 2001 |
O6-Benzylguanine potentiates BCNU but not busulfan toxicity in hematopoietic stem cells
GR Westerhof, JD Down, I Blokland, M Wood, A Boudewijn, AJ Watson, AT McGown, RE Ploemacher, GP Margison |
Experimental Hematology | 2001 |
Marrow protection – transduction of hematopoietic cells with drug resistance genes
T Moritz, DA Williams |
Cytotherapy | 2001 |
MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice
H Zhou, W Chen, X Qin, K Lee, L Liu, SD Markowitz, SL Gerson |
Oncogene | 2001 |
DNA repair and gene therapy: Implications for translational uses
M Limp-Foster, MR Kelley |
Environmental and Molecular Mutagenesis | 2000 |
Circadian variation inO6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects
C Marchenay, E Cellarier, F L�vi, C Rolhion, F Kwiatkowski, B Claustrat, JC Madelmont, P Chollet |
International Journal of Cancer | 2000 |
O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study
MR Middleton, SM Lee, A Arance, M Wood, N Thatcher, GP Margison |
International Journal of Cancer | 2000 |
Gene transfer to suppress bone marrow alkylation sensitivity
RB Roth, LD Samson |
Mutation Research/Reviews in Mutation Research | 2000 |
Proliferation is necessary for both repair and mutation in transgenic mouse cells
JH Bielas, JA Heddle |
Proceedings of the National Academy of Sciences | 2000 |
From the Cover: Proliferation is necessary for both repair and mutation in transgenic mouse cells
JH Bielas, JA Heddle |
Proceedings of the National Academy of Sciences | 2000 |
Enhanced in vivo repair of O4 -methylthymine by a mutant human DNA alkyltransferase
LP Encell, LA Loeb |
Carcinogenesis | 2000 |
Enhanced in vivo repair of O4-methylthymine by a mutant human DNA alkyltransferase
LP Encell, LA Loeb |
Carcinogenesis | 2000 |
Characterization of the P140K, PVP(138-140)MLK, and G156A O6-Methylguanine-DNA Methyltransferase Mutants: Implications for Drug Resistance Gene Therapy
BM Davis, JC Roth, L Liu, M Xu-Welliver, AE Pegg, SL Gerson |
Human Gene Therapy | 1999 |
Mice over-expressing human O6alkylguanine-DNA alkyltransferase selectively reduce O6methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea
E Allay, M Veigl, SL Gerson |
Oncogene | 1999 |
Drug resistance and DNA repair in leukaemia
MR Müller, J Thomale, MF Rajewsky, S Seeber |
Cytotechnology | 1998 |
Multiple Drug Resistance in Cancer 2
M Clynes |
1998 | |
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor
J Ma, Z L Fei, A Klein-Szanto, J M Gallo |
Clinical & Experimental Metastasis | 1998 |
LacZ and Interleukin-3 ExpressionIn Vivoafter Retroviral Transduction of Marrow-Derived Human Osteogenic Mesenchymal Progenitors
JA Allay, JE Dennis, SE Haynesworth, MK Majumdar, DW Clapp, LD Shultz, AI Caplan, SL Gerson |
Human Gene Therapy | 1997 |
Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents
ME Dolan |
Advanced Drug Delivery Reviews | 1997 |
Understanding and manipulating O6-methylguanine-DNA methyltransferase expression
RO Pieper |
Pharmacology & Therapeutics | 1997 |
Regulation of O6-methylguanine-DNA methyltransferase by methionine in human tumour cells
DM Kokkinakis, MA von Wronski, TH Vuong, TP Brent, SC Schold |
British Journal of Cancer | 1997 |
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials
E S Newlands, M F Stevens, S R Wedge, R T Wheelhouse, C Brock |
Cancer Treatment Reviews | 1997 |
Mismatch repair provokes chromosome aberrations in hamster cells treated with methylating agents or 6-thioguanine, but not with ethylating agents
MJ Armstrong, SM Galloway |
Mutation research | 1997 |
Retrovirus-mediated transfer of the human O6-Methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents
W Gang |
Biochemical Pharmacology | 1996 |
Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs
I Preuss, R Thust, B Kaina |
International Journal of Cancer | 1996 |
Analysis of O6-methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction
J Hansson |
European Journal of Cancer | 1996 |
Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea
JS Reese, ON Koç, KM Lee, L Liu, JA Allay, WP Phillips, SL Gerson |
Proceedings of the National Academy of Sciences | 1996 |
Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent
R Maze, JP Carney, MR Kelley, BJ Glassner, DA Williams, L Samson |
Proceedings of the National Academy of Sciences | 1996 |
Chemoprotection of normal tissues by transfer of drug resistance genes
JA Rafferty, I Hickson, N Chinnasamy, LS Lashford, GP Margison, TM Dexter, LJ Fairbairn |
Cancer and Metastasis Reviews | 1996 |
Drug Resistance
WN Hait |
1996 | |
O6-methylguanine-DNA methyltransferase activity in breast and brain tumors
I Preuss, I Eberhagen, S Haas, RH Eibl, M Kaufmann, GV Minckwitz, B Kaina |
International Journal of Cancer | 1995 |
O 6 -Alkylguanine-DNA Alkyltransferase: A Target for the Modulation of Drug Resistance
SL Gerson, JK Willson |
Hematology/Oncology Clinics of North America | 1995 |
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide
SM Lee, N Thatcher, D Crowther, GP Margison |
British Journal of Cancer | 1994 |
Mutagenesis and transgenic systems: Perspective from the mutagen, N-ethyl-N-nitrosourea
JG Burkhart, HV Malling |
Environmental and Molecular Mutagenesis | 1993 |
Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma
SM Lee, GP Margison, AA Woodcock, N Thatcher |
British Journal of Cancer | 1993 |
Preclinical pharmacology of the antitumor agentO-6-methylguanine in CDF1 mice
VI Avramis, KK Chan, MM Solorzano, Z Chen |
Cancer Chemotherapy and Pharmacology | 1993 |
Treatment of subcutaneous and intracranial brain tumor xenografts withO 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea
GM Felker, HS Friedman, ME Dolan, RC Moschel, C Schold |
Cancer Chemotherapy and Pharmacology | 1993 |
The Prevention of Thymic Lymphomas in Transgenic Mice by Human O 6 -Alkylguanine-DNA Alkyltransferase
LL Dumenco, E Allay, K Norton, SL Gerson |
Science | 1993 |
O6-Alkylguanine-DNA alkyltransferase activity in human malignant melanoma
S Moriwaki, C Nishigori, H Takebe, S Imamura |
Journal of Dermatological Science | 1992 |
The Saccharomyces cerevisiae MGT1 DNA repair methyltransferase gene: its promoter and entire coding sequence, regulation and in vivo biological functions
W Xiao, L Samson |
Nucleic Acids Research | 1992 |
Cyclophosphamide decreases O6-alkylguanine-DNA alkyltransferase activity in peripheral lymphocytes of patients undergoing bone marrow transplantation
SM Lee, D Crowther, JH Scarffe, M Dougal, RH Elder, JA Rafferty, GP Margison |
British Journal of Cancer | 1992 |
Modulation of nitrosourea resistance in human colon cancer by O6-methylguanine
SL Gerson, NA Berger, C Arce, SJ Petzold, JK Willson |
Biochemical Pharmacology | 1992 |
In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue
SM Lee, N Thatcher, D Crowther, GP Margison |
Cancer Chemotherapy and Pharmacology | 1992 |
Cloning and characterization of a 3-methyladenine DNA glycosylase cDNA from human cells whose gene maps to chromosome 16
L Samson, B Derfler, M Boosalis, K Call |
Proceedings of the National Academy of Sciences | 1991 |
Direct assay for O6-methylguanine-DNA methyltransferase and comparison of detection methods for the methylated enzyme in polyacrylamide gels and electroblots
GN Major, EJ Gardner, PD Lawley |
Biochemical Journal | 1991 |
The control of O6-methylguanine-DNA methyltransferase (MGMT) activity in mammalian cells: A pre-molecular view
BS Strauss |
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis | 1990 |
DNA Damage and Repair in Human Tissues
BM Sutherland, AD Woodhead |
1990 | |
Scientific Issues in Quantitative Cancer Risk Assessment
SH Moolgavkar |
1990 | |
Antineoplastic Drugs in 1990: A Review (Part II)1
DJ Black, RB Livingston |
Drugs | 1990 |
Role of 0(6)-alkylguanine DNA alkyltransferase in the implementation of the antitumor activity of N-nitrosoureas (a review)
LB Gorbacheva, GV Kukushkina |
Pharmaceutical Chemistry Journal | 1989 |
O6-methylguanine-DNA methyltransferase in lymphocytes of the elderly with and without Alzheimers' disease
JA Edwards, LG Wang, RB Setlow, E Kaminskas |
Mutation Research/DNAging | 1989 |
DNA Repair Mechanisms and Their Biological Implications in Mammalian Cells
MW Lambert, J Laval |
1989 | |
Cytotoxicity of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC) on Mer+, Mer+Rem- and Mer- cell lines: differential potentiation by 3-acetamidobenzamide
JM Lunn, AL Harris |
British Journal of Cancer | 1988 |
Increased sensitivity of lymphocytes from patients with systemic autoimmune diseases to DNA alkylation by the methylating carcinogen N-methyl-N-nitrosourea
PD Lawley, R Topper, AM Denman, W Hylton, ID Hill, G Harris |
Annals of the rheumatic diseases | 1988 |